Patients with locally advanced muscle-invasive bladder cancer may benefit from dose-dense gemcitabine and cisplatin. The treatment of preoperative dose-dense gemcitabine and cisplatin chemotherapies was well-tolerated and effective in patients with locally advanced muscle-invasive bladder cancer; however, more research is needed, an expert told CURE®. “The dose-dense part means to...

Dose-Dense Chemo for Muscle-Invasive Bladder Cancer May Be Feasible

Cancer Health

This week, the Food and Drug Administration (FDA) approved a new blood test to screen for colon cancer, according to an FDA announcement. Guardant Health’s Shield is not a replacement for colonoscopies but has potential to improve the low screening rates for colon cancer, the second leading cause of cancer-related death in the United States (lung cancer tops that list by far).

FDA Approves Blood Test for Colon Cancer

Patients with NSCLC taking five or more medications tended to have worse survival, highlighting the need for medication management, research showed. Older patients with advanced non-small cell lung cancer (NSCLC) receiving immunotherapy treatment tended to have worse survival outcomes if they were taking five or more other oral or inhaled medications, according to a study published in the Journal of Geriatric Oncology.

Polypharmacy May Shorten Survival in Lung Cancer

The Food and Drug Administration (FDA) on Aug. 6 approved VORANIGO, the first targeted therapy for Grade 2 Isocitrate dehydrogenase (IDH) mutant glioma, a type of brain tumor. Available to patients as a once-daily pill, VORANIGO is the first significant treatment breakthrough in nearly 25 years for Grade 2 IDH mutant glioma, the drug’s maker Servier explained.

FDA approves Servier’s VORANIGO for certain brain tumors

Researchers compared health-related quality of life among patients ages 60 and older with acute myeloid leukemia undergoing different chemotherapy regimens. Lower-intensity treatment with decitabine chemotherapy may be preferable over the current standard of intensive chemotherapy among fit older patients with acute myeloid leukemia (AML), researchers have found. Research published in...

Less-Intense Chemotherapy May Be Preferrable in Older Patients with AML

Incorporating information from common blood tests can enhance cancer risk assessment in patients with abdominal symptoms, according to a study publishing July 30th in the open-access journal PLOS Medicine by Meena Rafiq from University College London, UK, and colleagues. Early cancer detection is key to successful treatment. However, many undiagnosed...

Routine blood test results can improve cancer risk assessment in patients with abdominal symptoms

The FDA approved Sandoz’ Enzeevu, the fourth aflibercept biosimilar to be approved for Americans with age-related macular degeneration and other retinal eye diseases. This article was originally published on The Center for Biosimilars®. Sandoz secured another approval, this time for an aflibercept biosimilar.1 Enzeevu (aflibercept-abzv) is the fourth...

FDA Approves Biosimilar Enzeevu for Eye Conditions

Avidity Biosciences‘ delpacibart zotadirsen, or del-zota for short — formerly called AOC 1044 — was found to safely increase levels of dystrophin production to 25% of normal in people with Duchenne muscular dystrophy (DMD), according to new data from the EXPLORE44 trial. In the Phase 1/2 clinical...

Del-zota increases dystrophin in DMD patients, new trial data show

Community Voices represent independent, third-party users who have joined our contributor program but not yet verified their accounts. Community Voices are expected, like all users, to adhere to our Community Standards.

community_voice

Cooking With Maryann

This recipe is sooo tasty! It truly is for garlic lovers! It involves sautéing onions and mushrooms in butter and oil until golden, then adding wine to reduce. Garlic, thyme, and parsley are stirred in for flavor, followed by seasoning with salt and pepper. The dish is garnished with additional parsley and served warm, making for a savory, aromatic side. Here's what you'll need to make it:

Garlic Mushrooms in Brown Butter Herb Sauce

Inspire Medical Systems, a medical technology company focused on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA), announced the FDA approval of the Inspire V therapy system which includes the next generation neurostimulator and the associated Bluetooth patient remote and physician programmer. Inspire...

FDA Approves 'Mask-Free' Sleep Apnea Treatment Device

SON-080, a novel drug, may reduce chemotherapy-induced peripheral neuropathy in patients previously treated with chemotherapy. The novel drug SON-080 showed promise in the phase 1b portion of the SB211 trial (NCT05435742) focusing on persistent chemotherapy-induced peripheral neuropathy (CIPN) in patients previously treated with chemotherapy, according to a press release from Sonnet BioTherapeutics.1.

Novel Drug SON-080 May Reduce Peripheral Neuropathy From Chemotherapy

Florida State

Contributors represent independent, third-party users who have joined our contributor program and self-verified their accounts. They have also demonstrated their experience writing hard news for other outlets. Contributors are expected, like all users, to adhere to our Community Standards.

contributor

Jacksonville Today

Republican Donald Trump has a 7-point lead over Democrat Kamala Harris among Florida voters, 49% to 42%, according to a new poll from the University of North Florida. Four percent are backing another candidate, and 6% are undecided or didn’t answer.

New Florida poll: Trump leads; support strong for abortion and recreational weed

Colorado State

David Heitz

A bill quietly introduced this spring in the Colorado legislature to decriminalize the possession of drug paraphernalia obtained by harm reductionists has become law. As low-key as the legislation was introduced, the bill was signed into law without fanfare June 6. It garnered little to no media attention.

Colorado legalizes needles, pipes for meth and crack if obtained by harm reduction group

The Lens

This year’s area of low oxygen in the Gulf of Mexico is larger than average, the National Oceanic and Atmospheric Administration (NOAA) announced on Thursday. The “dead zone” is approximately 6,705 square miles , as measured last week. Within NOAA’s 38 years of measuring the dead zone, this year’s assessment marks the 12th-largest area of low to no oxygen, which can kill fish and marine life.

Gulf ‘dead zone’ larger than average, larger than expected for 2024, scientists announce

The FDA granted priority review to durvalumab in limited-stage small cell lung cancer after platinum-based concurrent chemoradiotherapy. The FDA has granted priority review to the supplemental biologics license application (sBLA) seeking the approval of durvalumab (Imfinzi) for the treatment of patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based concurrent chemoradiotherapy.1.

FDA Grants Priority Review to Durvalumab for LS-SCLC After Concurrent Chemoradiotherapy

UGN-102 has the potential to be the first FDA-approved treatment for low-grade intermediate-risk non-muscle invasive bladder cancer, UroGen says. UroGen has completed its New Drug Application (NDA) submission for UGN-102 (mitomycin) for intravesical solution, suggesting that it has the potential to become the first FDA-approved treatment for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The NDA submission is supported by results from the Phase III ENVISION trial, which demonstrated that patients treated with UGN-102 had a 79.6% complete response (CR) rate at three months following the first instillation.1.

UroGen Pharma Submits FDA New Drug Application for UGN-102, a Potential Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Neoadjuvant/adjuvant sacituzumab govitecan showed encouraging intratumoral concentrations in patients with brain metastases as well as glioblastoma. The antibody-drug conjugate (ADC), sacituzumab govitecan (Trodelvy), given in the neoadjuvant and adjuvant settings, displayed promising preliminary activity in patients undergoing craniotomy for breast cancer with brain metastases or those with recurrent glioblastoma (GBM), according to a phase 0 window-of-opportunity study (NCT03995706) published in Nature Communications.

Sacituzumab Govitecan Shows Preliminary Activity in Patients With Brain Mets, GBM

Approximately one-third of patients with systemic mastocytosis (SM) have bronchial or lung lesions as identified via chest computed tomography (CT) scans, according to a letter to the editor of Clinical and Translational Allergy. SM is characterized by the accumulation of clonal mast cells in various organs, including the lungs. The...

One-Third of Patients With SM Have Bronchial or Lung Lesions

Thyroid lymphoma is an extremely rare but highly treatable cancer that affects the thyroid gland. It can cause a mass in the neck, difficulty swallowing, and shortness of breath. Most cases of thyroid cancer start when thyroid gland cells become cancerous. Thyroid lymphoma, meanwhile, is a disease that happens when...

What to Know About Thyroid Lymphoma

Livdelz is an oral therapy to treat patients with primary biliary cholangitis, a progressive autoimmune disease. It is expected to be available in pharmacies next week. The FDA has granted accelerated approval for Livdelzi (seladelpar) to treat patients with primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA). PBC is a progressive autoimmune disease that results from the destruction of the bile ducts in the liver. This leads to inflammation, scarring and cirrhosis. The disease affects mostly women.

FDA Grants Accelerated Approval for Rare Liver Disease Drug

NewsBreak

FDA Approves Presurgical, Postsurgical Imfinzi in Some With NSCLC

Imfinzi has been approved as a presurgical treatment with platinum-based chemotherapy and postsurgical treatment alone in surgically removable NSCLC. The Food and Drug Administration (FDA) has...

FDA Approves Presurgical, Postsurgical Imfinzi in Some With NSCLC

Comments / 0